JCC Investigational New Drug Fellowship in Medical Oncology, Canada, and applications are submitted till July 1, 2015. The Juravinski Cancer Centre awards a 1-2 year Investigational New Drug Fellowship in Medical Oncology. These studies have involved the full-spectrum of initial phase I studies to determine maximum tolerated dose, as well as subsequent phase II and III efficacy studies. All qualified candidates are encouraged to apply. However, Canadian citizens and permanent residents will be considered first for these positions. The salary for the fellowship will be at the PGY6 level. The fellow will be expected to write an abstract/manuscript for any publications arising from protocols in which a major role was played. Full details:
School(Institutions/ Country): | Canada
Level: This is a one or two year fellowship program.
Field(s): Fellowship is awarded in the area of Medical Oncology. The areas of focus for early phase drug development at the JCC include: targeting cell signalling resulting in the malignant phenotype, interrupting processes involved in invasion and metastasis, immunomodulation and immunotherapeutic approaches.
Deadline: July 1, 2015.
Funded By: The Juravinski Cancer Centre, Canada
Beneficiaries(Target Groups): JCC Investigational New Drug Fellowship is targeted for both Canadian and international applicants are eligible to apply for this fellowship. However, Canadian citizens and permanent residents will be considered first for these positions.
‣ No. of awards: One fellowship is available.
‣ Scholarship Tenure : Fellowship is awarded for 1 to 2 year.
‣Value of Scholarship : The salary for the fellowship will be at the PGY6 level. The fellow will be expected to write an abstract/manuscript for any publications arising from protocols in which a major role was played. The fellow will be funded for travel to one national and one international meeting annually to present the results on the trials in which there was major involvement.
‣ The Department of Oncology located at the Juravinski Cancer Centre is offering a 1-2 year Investigational New Drug (IND) Fellowship.
‣ The Juravinski Cancer Centre (JCC) in Hamilton, Ontario, Canada is one of the five largest cancer centres in North America, and has evolved to become one of the leading Canadian centres in the study of Investigational New Drugs (IND).
‣ In addition to being the top accruer to IND studies to the National Institute of Canada Clinical Trials Group (NCIC-CTG) over the past five years, the centre has also been actively involved with industry-sponsored IND studies.
‣ Applicants must have completed specialty in Medical Oncology and have CPSO licensing to practice in the Province of Ontario.
‣ All qualified candidates are encouraged to apply. However, Canadian citizens and permanent residents will be considered first for these positions.
‣ McMaster University is strongly committed to employment equity within its community, and to recruiting a diverse faculty and staff. The University encourages applications from all qualified candidates, including women, members of visible minorities, Aboriginal peoples, members of sexual minorities and persons with disabilities.
‣ Invitations for interviews will be given to selected applicants. Incomplete applications will not be accepted.
Scholarship Application Method
‣ Scholarship Applications are due on July 1, 2015.
‣ Application forms and guidelines can be download from the official website
‣ It is important to read the application procedure, and visit the official websites (link found below) for detailed information on how to apply for this scholarship.